Evaluation of 227 drugs for in vitro inhibition of cytochrome P450 2B6. - Wikidata - awgldk - TriplyDB

Evaluation of 227 drugs for in vitro inhibition of cytochrome P450 2B6.

Evaluation of 227 drugs for in vitro inhibition of cytochrome P450 2B6.

http://www.wikidata.org/entity/Q51928851

about

Crystal structure of a cytochrome P450 2B6 genetic variant in complex with the inhibitor 4-(4-chlorophenyl)imidazole at 2.0-A resolution Conformational Adaptation of Human Cytochrome P450 2B6 and Rabbit Cytochrome P450 2B4 Revealed upon Binding Multiple Amlodipine Molecules A Structural Snapshot of CYP2B4 in Complex with Paroxetine Provides Insights into Ligand Binding and Clusters of Conformational States Structural and Thermodynamic Basis of (+)-α-Pinene Binding to Human Cytochrome P450 2B6 OPRM1 and CYP2B6 gene variants as risk factors in methadone-related deaths In vitro analysis and quantitative prediction of efavirenz inhibition of eight cytochrome P450 (CYP) enzymes: major effects on CYPs 2B6, 2C8, 2C9 and 2C19 Determination of metabolic profile of anti-malarial trioxane CDRI 99/411 in rat liver microsomes using HPLC.Effects of sertraline on the pharmacokinetics of bupropion and its major metabolite, hydroxybupropion, in mice.Comparison of in vitro metabolism of ticlopidine by human cytochrome P450 2B6 and rabbit cytochrome P450 2B4 CYP2B6: new insights into a historically overlooked cytochrome P450 isozyme Effect of proton pump inhibitors on the serum concentrations of the selective serotonin reuptake inhibitors citalopram, escitalopram, and sertraline Polymorphic variants of cytochrome P450 2B6 (CYP2B6.4-CYP2B6.9) exhibit altered rates of metabolism for bupropion and efavirenz: a charge-reversal mutation in the K139E variant (CYP2B6.8) impairs formation of a functional cytochrome p450-reductase c Risk of bleeding associated with combined use of selective serotonin reuptake inhibitors and antiplatelet therapy following acute myocardial infarction Development of an in vitro system with human liver microsomes for phenotyping of CYP2C9 genetic polymorphisms with a mechanism-based inactivator SNP genetic polymorphisms of MDR-1, CYP1A2 and CYPB11 genes in four canine breeds upon toxicological evaluation.Mechanism-based inactivation of cytochrome P450 2B6 by methadone through destruction of prosthetic heme Bioactivation of chlorpyrifos by CYP2B6 variants.Interactions between CYP2E1 and CYP2B4: effects on affinity for NADPH-cytochrome P450 reductase and substrate metabolism.Effects of clopidogrel and itraconazole on the disposition of efavirenz and its hydroxyl metabolites: exploration of a novel CYP2B6 phenotyping index Use of enantiomeric bupropion and hydroxybupropion to assess CYP2B6 activity in glomerular kidney diseases In vitro evaluation of reversible and irreversible cytochrome P450 inhibition: current status on methodologies and their utility for predicting drug-drug interactions.Pharmacokinetic Effects of Isavuconazole Coadministration With the Cytochrome P450 Enzyme Substrates Bupropion, Repaglinide, Caffeine, Dextromethorphan, and Methadone in Healthy Subjects.Chemical inhibitors of cytochrome P450 isoforms in human liver microsomes: a re-evaluation of P450 isoform selectivity.Metabolic-based drug-drug interactions prediction, recent approaches for risk assessment along drug development.Metabolic differences of current thienopyridine antiplatelet agents.The Effect of Gene Variants on Levonorgestrel Pharmacokinetics When Combined With Antiretroviral Therapy Containing Efavirenz or Nevirapine.Effect of Brain CYP2B Inhibition on Brain Nicotine Levels and Nicotine Self-Administration.Stereoselective metabolism of bupropion by cytochrome P4502B6 (CYP2B6) and human liver microsomes.[Depression in cancer patients].Decreased susceptibility of the cytochrome P450 2B6 variant K262R to inhibition by several clinically important drugs.Clarithromycin, a potent inhibitor of CYP3A, greatly increases exposure to oral S-ketamine.Comparison of mechanism-based inhibition of human cytochrome P450 2C19 by ticlopidine, clopidogrel, and prasugrel.Population Genetic-Based Pharmacokinetic Modeling of Methadone and its Relationship with the QTc Interval in Opioid-Dependent Patients.β-Arrestin2 influences the response to methadone in opioid-dependent patients.Analysis of Species-Selectivity of Human, Mouse and Rat Cytochrome P450 1A and 2B Subfamily Enzymes using Molecular Modeling, Docking and Dynamics Simulations.Exposure to oral S-ketamine is unaffected by itraconazole but greatly increased by ticlopidine.Near-fatal tramadol cardiotoxicity in a CYP2D6 ultrarapid metabolizer.Determination of metabolic profile of novel triethylamine containing thiophene S006-830 in rat, rabbit, dog and human liver microsomes.Functional expression and comparative characterization of four feline P450 cytochromes using fluorescent substrates.Characterization of feline cytochrome P450 2B6.

P2860

Q24294558-C158E1EC-9025-4F8E-A973-EB088E994E6B Q27671627-E5221818-6442-47DF-AE07-EE1C68D98747 Q27677947-0734E86C-4B95-489F-8F61-2EC0280E306D Q27678713-B295DE25-59CC-4B9A-AC16-CE62F3264455 Q28289166-9CF2C112-9036-4033-B668-C404F39C4ACA Q33821729-6404CC61-0964-4A2F-BE20-3F22F3FD32F8 Q33876677-62687CBA-58ED-4B92-8A21-D6A61916C297 Q34217306-0FFDB284-25B2-4568-9AC8-1F84852D2DB6 Q34702595-8FD35E06-8EA4-473C-9266-DC87BEFC9AAC Q34824471-65CDA77E-4611-46B9-8936-04EF287478AA Q34978292-2EE3EA4A-1300-49DE-BBA1-AAEFDE8BC486 Q35188159-9DEAE54E-3FAC-48B9-BF46-408E4E98AEC9 Q35551130-0DEB5394-3473-4364-87C1-CB803A5842F9 Q35846894-F0E6D6DC-EB81-4BB6-B032-87C801662167 Q36105479-31D490C1-69B1-4871-B88C-F8263735DE0C Q36174280-E97B2580-F508-4241-9CC4-88940B6D2D52 Q36462008-AC7DA928-C02D-44A1-8C3B-6672F8D736ED Q36497669-5EA6B457-956E-4D92-97BE-CD25BF1B4C46 Q36562516-7A26AFA5-A796-4DC5-9091-FD417BEA1E9F Q36733922-A77A1076-9049-4CD5-9F83-B883A3FBB637 Q37237438-1B8FCA9A-CFD6-4307-B948-9748FC3A72C7 Q37631831-D6AF8B43-F96F-45C8-8DFE-3235D7558DEC Q37845170-0E8A9070-09F3-42F8-ADE6-BD43BA4F1B6B Q37965706-60AA0052-5441-40B3-91FC-F685540AF638 Q38071707-AEC38152-753E-4443-9FAD-65D79A4BBBA1 Q38851258-5A95DFBB-170A-4ABE-9BB9-ED2A1C610B72 Q40443135-FA7F336B-D816-4152-90F1-1A9439AC61E7 Q41153557-7693BEE6-83D1-4E51-8227-9DEB4C84A9A3 Q41613902-C39D3E6C-8EAB-4C0D-BB4F-E6DE9BEB1B19 Q42217729-017FCBF4-5D6E-4794-A768-948CAB6BEC84 Q43246296-B728427D-B5A8-4C7C-ABB5-BE6FB3140853 Q43257605-CB4AAE2B-6BD2-426F-9869-CE14C4859283 Q44337894-14C47F87-7131-4A04-ADA4-EAB8D2FB3668 Q44346717-7C1A9C79-6E68-4D3F-B2E5-D6C4BEC2C679 Q46394683-B1E4695D-8638-4323-8060-6C31D35D37FE Q48251035-7B74F96C-6B9B-44D7-937A-12178D6DC7A5 Q48846038-724C6645-1A69-48E5-AE3C-E68A76890EA6 Q50559432-7DB4B0DC-5CD3-49FB-9C1C-53B5F3FBAC0F Q51328715-FEC63DD8-D07A-4A3A-BF70-056A57FE7E63 Q51541276-D192C24B-4BDC-4BE6-A0D0-4BB5DB7796F6

P2860

Evaluation of 227 drugs for in vitro inhibition of cytochrome P450 2B6.

http://www.wikidata.org/entity/Q51928851

description

2006 nî lūn-bûn

@nan

2006年の論文

@ja

2006年学术文章

@wuu

2006年学术文章

@zh

2006年学术文章

@zh-cn

2006年学术文章

@zh-hans

2006年学术文章

@zh-my

2006年学术文章

@zh-sg

2006年學術文章

@yue

2006年學術文章

@zh-hant

name

Evaluation of 227 drugs for in vitro inhibition of cytochrome P450 2B6.

@en

Evaluation of 227 drugs for in vitro inhibition of cytochrome P450 2B6.

@nl

type

label

Evaluation of 227 drugs for in vitro inhibition of cytochrome P450 2B6.

@en

Evaluation of 227 drugs for in vitro inhibition of cytochrome P450 2B6.

@nl

prefLabel

Evaluation of 227 drugs for in vitro inhibition of cytochrome P450 2B6.

@en

Evaluation of 227 drugs for in vitro inhibition of cytochrome P450 2B6.

@nl

P1433

Q51928851-DAD7D8B9-61DD-4948-BB14-D63ED9691407

P1476

Q51928851-2CA440C2-8D1B-4478-8FAD-C420815AD77A

P2093

Q51928851-183D1D44-F044-4139-B495-04327FDCAED4

Q51928851-1947A7CE-2999-47E6-9E79-CA18309CA9F0

Q51928851-2AC466AA-2B8F-4F2F-B4CD-A4CE46F7D118

P2860

Q51928851-25BEE35D-5759-45D1-93F8-6574E5F88EFD

Q51928851-29A3E1A0-F63F-40B2-B304-A1552F8AC509

Q51928851-3AD66E2E-4D2F-4425-9F16-6BA96E6FFB45

Q51928851-46C1C437-2986-4A77-ADDC-3CE6C775C41D

Q51928851-5288D96B-F857-41D5-A2FC-CC03AC5C7A2B

Q51928851-52BB09D5-D9A3-4D2B-B472-EA4169530730

Q51928851-5330C765-4323-4903-A5DD-343481C51E54

Q51928851-59D1AC7D-DAF1-462C-96E9-FEF5986F72D1

Q51928851-6A2AA644-1E5B-46E3-AD2C-5389659A6674

Q51928851-77C4AAA5-7561-4821-848F-527CCE8D721D

P304

Q51928851-32548623-241C-45FC-A189-A06A4F9ECA89

P31

Q51928851-7A562B34-E05F-4D8C-B3E0-21C7081C4716

P356

Q51928851-F1B14EBC-6836-43EB-8C4C-C755CE017AE0

P433

Q51928851-C74816AD-8B0D-40E5-95A1-A77469A69A4D

P478

Q51928851-81409F2C-B293-411B-8693-328EEEA227BA

P577

Q51928851-635925F7-2765-4829-AD1C-27B237477B58

P698

Q51928851-35BBB7CB-97B6-471C-BE59-01329A617D54

P356

0091270006293753

P1433

The Journal of Clinical Pharmacology

P1476

Evaluation of 227 drugs for in vitro inhibition of cytochrome P450 2B6.

@en

P2093

Angela V Astuccio

http://www.w3.org/2001/XMLSchema#string

R Scott Obach

http://www.w3.org/2001/XMLSchema#string

Robert L Walsky

http://www.w3.org/2001/XMLSchema#string

P2860

Human extrahepatic cytochromes P450: function in xenobiotic metabolism and tissue-selective chemical toxicity in the respiratory and gastrointestinal tracts

Sertraline is metabolized by multiple cytochrome P450 enzymes, monoamine oxidases, and glucuronyl transferases in human: an in vitro study

Examination of 209 drugs for inhibition of cytochrome P450 2C8

Quantitative prediction of in vivo drug-drug interactions from in vitro data based on physiological pharmacokinetics: use of maximum unbound concentration of inhibitor at the inlet to the liver.

The utility of in vitro cytochrome P450 inhibition data in the prediction of drug-drug interactions.

Efavirenz plasma levels can predict treatment failure and central nervous system side effects in HIV-1-infected patients.

The role of CYP2B6 in human xenobiotic metabolism.

Contribution of CYP3A4, CYP2B6, and CYP2C9 isoforms to N-demethylation of ketamine in human liver microsomes.

Role of hepatic and intestinal cytochrome P450 3A and 2B6 in the metabolism, disposition, and miotic effects of methadone.

Human cytochrome P450 enzymes: a status report summarizing their reactions, substrates, inducers, and inhibitors.

P304

1426-1438

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1177/0091270006293753

http://www.w3.org/2001/XMLSchema#string

P433

12

http://www.w3.org/2001/XMLSchema#string

P478

46

http://www.w3.org/2001/XMLSchema#string

P577

2006-12-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

17101742

http://www.w3.org/2001/XMLSchema#string